Key takeaways
Ubrelvy (ubrogepant) and Aimovig (erenumab) are both medications used to address migraines, but they have several differences. Ubrelvy is taken orally to treat sudden migraine attacks in adults, while Aimovig is an injection used to prevent migraines. Ubrelvy is a calcitonin gene-related peptide (CGRP) receptor blocker that works by stopping pain and inflammation during a migraine, and it can be taken with or without food. In contrast, Aimovig is a monoclonal antibody that blocks CGRP receptors to prevent migraines and is administered once a month. Ubrelvy can cause side effects like nausea, sleepiness, and dry mouth, whereas Aimovig may cause injection site reactions, constipation, and potentially high blood pressure. Additionally, Ubrelvy interacts with many medications, while Aimovig requires proper injection technique and has specific storage instructions.
